Search
Neogenomics Inc
NEOAdd to Watchlist
14.970USD
+0.380+2.60%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.94BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.60%
5 Days
+16.05%
1 Month
+43.39%
6 Months
+27.30%
Year to Date
+27.30%
1 Year
+102.02%
Key Figures
14.550Open
15.195High
3.23MVolume
LossP/E TTM
40.16P/E Dynamic
--Dividend TTM
2.49%Turnover Ratio
14.590Prev. Close
14.540Low
37.39MTurnover
LossP/E Static
2.34P/B
0.00%Div Yield TTM
-6.73%ROA
13.74052wk High
0.69Volume Ratio
-78.73MNet Profit
129.65MShares
-0.7722EPS TTM
1.81Beta
-11.56%ROE
4.72052wk Low
4.49%Amplitude
43.32%Gross Margin
1.94BMarket Cap
12.71Reward/Risk
3.48%Risk Rate
TradingKey Stock Score of Neogenomics Inc
Currency: USD Updated: 2026-07-01Key Insights
Neogenomics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 30 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.06.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neogenomics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Neogenomics Inc Highlights
StrengthsRisks
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.93% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 727.33M.
Fairly Valued
The company’s latest PE is -19.39, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 156.61M shares, increasing 4.58% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 189.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.79.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
15.056
Target Price
+3.19%
Upside Space
Neogenomics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neogenomics Inc Info
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Ticker SymbolNEO
CompanyNeogenomics Inc
CEOZook (Antony P)
Websitehttps://neogenomics.com/
Related Instruments
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%
+0.78%Popular Instruments
52371.200
+116.900 (+0.22%)
29941.000
+141.700 (+0.48%)
7500.100
+24.600 (+0.33%)
14931.000
-424.000 (-2.76%)
69684.000
+199.000 (+0.29%)
6297.500
+22.100 (+0.35%)
67.644
-0.324 (-0.48%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4058.080
+27.310 (+0.68%)
FAQs
What is the current price of Neogenomics Inc (NEO)?
The current price of Neogenomics Inc (NEO) is 14.97.
What is the symbol of Neogenomics Inc?
The ticker symbol of Neogenomics Inc is NEO.
What is the 52-week high of Neogenomics Inc?
The 52-week high of Neogenomics Inc is 13.74.
What is the 52-week low of Neogenomics Inc?
The 52-week low of Neogenomics Inc is 4.72.
What is the market capitalization of Neogenomics Inc?
The market capitalization of Neogenomics Inc is 1.94B.
Is Neogenomics Inc (NEO) currently rated as Buy, Hold, or Sell?
According to analysts, Neogenomics Inc (NEO) has an overall rating of Buy, with a price target of 15.06.
What is the Earnings Per Share (EPS TTM) of Neogenomics Inc (NEO)?
The Earnings Per Share (EPS TTM) of Neogenomics Inc (NEO) is -0.84.